Lazard Asset Management’s Maravai LifeSciences MRVI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-420,360
Closed -$2.62M – 2135
2026
Q2
$2.62M Sell
420,360
-427,439
-50% -$1.85M ﹤0.01% 860
2026
Q1
$2.4M Sell
847,799
-170,919
-17% -$579K ﹤0.01% 812
2025
Q4
$3.31M Sell
1,018,718
-521,508
-34% -$1.76M 0.01% 683
2025
Q3
$4.42M Buy
1,540,226
+89,805
+6% +$229K 0.01% 611
2025
Q2
$3.5M Buy
1,450,421
+44,128
+3% +$92.7K ﹤0.01% 839
2025
Q1
$3.11M Sell
1,406,293
-41,421
-3% -$164K ﹤0.01% 829
2024
Q4
$7.89M Buy
1,447,714
+127,672
+10% +$821K 0.01% 526
2024
Q3
$11M Buy
1,320,042
+169,468
+15% +$1.46M 0.01% 447
2024
Q2
$8.24M Buy
1,150,574
+785,415
+215% +$6.78M 0.01% 553
2024
Q1
$3.16M Buy
365,159
+359,411
+6,253% +$2.43M ﹤0.01% 761
2023
Q4
$37K Buy
5,748
+1,934
+51% +$12.5K ﹤0.01% 1971
2023
Q3
$37K Buy
3,814
+159
+4% +$1.75K ﹤0.01% 1942
2023
Q2
$44K Sell
3,655
-5,695
-61% -$76.9K ﹤0.01% 1874
2023
Q1
$130K Buy
9,350
+6,027
+181% +$86.6K ﹤0.01% 1433
2022
Q4
$47K Buy
3,323
+3,283
+8,208% +$51.7K ﹤0.01% 1849
2022
Q3
$1K Sell
40
-61
-60% -$1.53K ﹤0.01% 2259
2022
Q2
$2K Hold
101
– – ﹤0.01% 2295
2022
Q1
$3K Sell
101
-211
-68% -$7.07K ﹤0.01% 2220
2021
Q4
$13K Sell
312
-351,638
-100% -$14.2M ﹤0.01% 2103
2021
Q3
$17.3M Sell
351,950
-1,366,771
-80% -$66.7M 0.02% 517
2021
Q2
$71.7M Sell
1,718,721
-1,642,546
-49% -$63.7M 0.08% 215
2021
Q1
$120M Sell
3,361,267
-54,030
-2% -$1.79M 0.15% 127
2020
Q4
$95.8M Buy
+3,415,297
New +$95.1M 0.12% 153

Other funds holding MRVI

Lazard Asset Management's MRVI Position: Q3 2026 in Review

Lazard Asset Management sold out of Maravai LifeSciences (MRVI) in Q3 2026, closing a stake of 420,360 shares — an estimated $2.62M sold.

Lazard Asset Management first reported a position in MRVI in Q4 2020 and held it in 23 quarters. The position peaked at $120M in Q1 2021. 202 funds tracked by Wall St. Rank hold MRVI as of Q3 2026.

  • Lazard Asset Management reported no remaining Maravai LifeSciences position as of Q3 2026 after selling out during the quarter.
  • Lazard Asset Management sold 420,360 Maravai LifeSciences shares in Q3 2026, an estimated $2.62M.
  • Lazard Asset Management first reported a position in Maravai LifeSciences in Q4 2020 and held it in 23 quarters.
  • Lazard Asset Management's Maravai LifeSciences position peaked at $120M in Q1 2021.
  • 202 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q3 2026.

Based on Lazard Asset Management's 13F filing for Q3 2026, filed 16 Nov 2026.